If proven safe and effective, the vaccine could be an important tool to stop the tick-borne disease that affects nearly half a million Americans a year.
drove down interest and its manufacturer, GlaxoSmithKline, withdrew it.
VLA15 is delivered in three primary doses followed by a booster. Half the volunteers will receive a saline placebo for the first three doses and half will get a saline placebo as a booster, the company said. In earlier trials in both labs and people, the vaccine"demonstrated a strong immune response and satisfactory safety profile," the companies said.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Pfizer, French firm starting testing of major Lyme disease vaccineResearchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years -- in hopes of better fighting the tick-borne threat.
Weiterlesen »
Pfizer Begins Trial for Lyme Disease VaccineIf the trial succeeds, the vaccine could be the first human vaccine for the tick-borne illness in the US in two decades.
Weiterlesen »
Pfizer just started a late-stage clinical trial of a Lyme disease vaccineIf the trial succeeds, the vaccine could be the first human immunization for Lyme disease in the U.S. in two decades.
Weiterlesen »
Pfizer Begins Trial for Lyme Disease VaccinePfizer has launched a late-stage clinical trial to test a vaccine that could protect against Lyme disease, the company announced Monday.
Weiterlesen »
What the Lyme Disease Vaccine Could Mean for People Living With Long-Term SymptomsNow entering late-stage clinical trials, the vaccine could be approved as soon as 2025.
Weiterlesen »
With Lyme a Growing Problem, Long-Awaited Test of Possible Vaccine is Getting UnderwayLyme is a growing problem, with cases rising and warming weather helping ticks expand their habitat.
Weiterlesen »